Transplantation Diagnostics Global Market – Forecast To 2022

Publishing Date : August, 2016
Report Code : HCBT0109
Price:
Single license $4,500
Site license $6,300
Global license $9,000


Transplantation is a surgical procedure of transferring organ, tissue or cell taken from one part of the body and grafted into another area of the same individual or another individual of same species or different species. The solid organ, tissue and stem cell transplantation field has evolved from a clinical experiment to routine and reliable practice, which has proven to be clinically effective, life-saving and cost-effective. The transplantation diagnostics market is segmented based on the technology, product type, applications, end users and geography. By technology, the market is divided into molecular and non-molecular methods. By application, the transplantation diagnostics market is divided into diagnostic and research segments. By product, the transplantation diagnostics market is divided into instruments, consumables, software and services, assays and kits. By end users, the transplantation market is segmented into hospital and transplant centres, Research laboratories and academic institutes. Geographical wise, the transplantation market is segmented into North America, Europe, Asia- Pacific and rest of the world.

Among the transplantation diagnostics by technology, the non-molecular method is dominating the market by occupying the largest share and the molecular method is expected to grow at the highest CAGR from 2015 to 2022. The transplantation diagnostics market by product type is segmented into three major divisions such as instruments, consumables and software & services. Among these, consumables account for largest share and is growing at a strong CAGR from 2015 to 2022. By applications, is segmented into two major divisions such as diagnostic and research. Among these, diagnostic accounts for largest share as well as a fastest growing segment. The end-users market of transplantation diagnostics market is segmented into three major divisions, hospital & transplant centres, diagnostic laboratories and research laboratories & academic institutions. Among these, hospital and transplant centres account for largest share and growing at a strong growth rate. 

The transplantation diagnostics market is expected to grow at a high double-digit CAGR to reach $2,059.2 million by 2022. The factors driving the growth of this market are a high incidence of organ and tissue transplantation procedures across the world, increasing geriatric population, coupled with an increasing population base for chronic disease, increasing healthcare awareness are likely to propel the market. In addition to this, increasing demand for early detection through non-invasive testing procedures like cell-free DNA, increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to transplantation, high cost and non-affordability in developed as well as in low-and middle-income countries and unfavourable reimbursement policies are hampering the growth of the market. The threats for the transplantation diagnostics market include the significant gap between the number of organs donated and the number of organs required.

The transplantation diagnostics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the transplantation diagnostics market include Abbott Laboratories, Inc. (U.S.), Biofortuna Ltd (U.K.), Bio-Rad Laboratories, Inc. (U.S.), CareDx, Inc. (U.S.), Illumina, Inc. (U.S.), Immucor, Inc.(U.S.), Linkage biosciences (U.S.), Qiagen N.V. (Netherlands), Roche (Switzerland), Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASE IN THE RATE OF SOLID ORGAN, TISSUE AND STEM CELL TRANSPLANTATION
        • 3.3.1.2     INCREASE IN GERIATRIC POPULATION COUPLED WITH CHRONIC DISEASES
        • 3.3.1.3     INCREASE IN RESEARCH GRANTS AND FUNDING
        • 3.3.1.4     INCREASING DEMAND FOR EARLY DETECTION THROUGH NON-INVASIVE TESTING PROCEDURES USING CELL-FREE DNA
        • 3.3.1.5     GROWING AWARENESS AMONG PEOPLE FOR ORGAN DONATION AND INCREASE IN HEALTHCARE EXPENDITURE
        • 3.3.1.6     TECHNOLOGICAL SHIFT FROM SEROLOGICAL ASSAYS TO GENE-BASED HLA PROFILING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH DEVICE COST AND NON-AFFORDABILITY
        • 3.3.2.2     LIMITED MEDICAL REIMBURSEMENTS FOR ORGAN DONATION AND TRANSPLANTATION PROCEDURES
        • 3.3.2.3     ETHICAL ISSUES RELATED TO TRANSPLANTATION
        • 3.3.2.4     SIGNIFICANT GAP BETWEEN THE NUMBER OF ORGANS DONATED AND THE NUMBER OF ORGANS REQUIRED ANNUALLY IS A MAJOR CHALLENGE LIMITING THE GROWTH OF THE GLOBAL TRANSPLANT DIAGNOSTIC MARKET
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     INDIA
      • 3.4.4     CHINA
      • 3.4.5     JAPAN
    • 3.5     PORTER'S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     COMPETITIVE RIVALRY
      • 3.5.4     BARGAINING POWER OF SUPPLIERS
      • 3.5.5     BARGAINING POWER OF BUYERS
    • 3.6     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
    • 3.7     RECENT AND UPCOMING PRODUCTS
  • 4     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     MOLECULAR METHODS
      • 4.2.1     PCR BASED MOLECULAR METHODS
        • 4.2.1.1     SSP-PCR
        • 4.2.1.2     SSO-PCR
        • 4.2.1.3     OTHERS
          • 4.2.1.3.1     SNP-PCR
          • 4.2.1.3.2     RFLP-PCR
      • 4.2.2     SEQUENCING BASED MOLECULAR METHODS
        • 4.2.2.1     NGS
        • 4.2.2.2     SANGER SEQUENCING
    • 4.3     NON-MOLECULAR METHODS
      • 4.3.1     SEROLOGICAL TESTS
      • 4.3.2     MIXED LYMPHOCYTE CULTURE ASSAY
      • 4.3.3     FLOW CYTOMETRY
  • 5     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY PRODUCT TYPE
    • 5.1     INTRODUCTION
    • 5.2     INSTRUMENTS
    • 5.3     CONSUMABLES
    • 5.4     SOFTWARE & SERVICES
  • 6     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY SCREENING METHODS
    • 6.1     INTRODUCTION
    • 6.2     PRE-TRANSPLANTATION SCREENING
    • 6.3     POST-TRANSPLANTATION SCREENING
  • 7     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
    • 7.1     INTRODUCTION
    • 7.2     DIAGNOSTIC (MEDICAL) APPLICATIONS
      • 7.2.1     SOLID ORGAN TRANSPLANTATION DIAGNOSTICS
        • 7.2.1.1     KIDNEY TRANSPLANTATION
        • 7.2.1.2     HEART TRANSPLANTATION
        • 7.2.1.3     LIVER TRANSPLANTATION
        • 7.2.1.4     OTHER TRANSPLANTATION
      • 7.2.2     STEM CELL TRANSPLANTATION
      • 7.2.3     TISSUE BASED TRANSPLANTATION
    • 7.3     RESEARCH APPLICATIONS
  • 8     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY END-USERS
    • 8.1     INTRODUCTION
    • 8.2     HOSPITALS AND TRANSPLANT CENTRES
    • 8.3     DIAGNOSTIC LABORATORIES
    • 8.4     RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
  • 9     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY REGION
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     CANADA
    • 9.3     EUROPE
      • 9.3.1     GERMANY
      • 9.3.2     SPAIN
    • 9.4     ASIA-PACIFIC
      • 9.4.1     CHINA
      • 9.4.2     INDIA
      • 9.4.3     AUSTRALIA
    • 9.5     REST OF THE WORLD
  • 10     COMPANY DEVELOPMENTS
    • 10.1     INTRODUCTION
      • 10.1.1     ACQUISTIONS & AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS A MAJOR GROWTH STRATEGY OF TRANSPLANTATION DIAGNOSTICS MARKET PLAYERS
    • 10.2     ACQUISITIONS
    • 10.3     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
    • 10.4     NEW PRODUCT LAUNCH
    • 10.5     APPROVALS
    • 10.6     OTHER DEVELOPMENTS
  • 11     COMPANY PROFILES
    • 11.1     ABBOTT LABORATORIES, INC.
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BIOFORTUNA LTD
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     BIO-RAD LABORATORIES
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     CAREDX, INC.
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     ILLUMINA, INC.
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     IMMUCOR, INC.
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     LINKAGE BIOSCIENCES, INC.
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     QIAGEN N.V.
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     ROCHE HOLDINGS AG
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     THERMO FISHER SCIENTIFIC, INC.
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 2     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 3     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 4     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 5     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 6     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 7     MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 8     MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 9     PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 10     PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 11     SSP-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 12     SSO-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 13     OTHERS BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 14     SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 15     SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 16     NGS BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 17     SANGER BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 18     NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 19     NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 20     SEROLOGICAL TESTS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 21     MIXED LYMPHOCYTE CULTURE ASSAY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 22     FLOW CYTOMETRY BASED NON-MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 23     TRANSPLANTATION DIAGNOSTICS GLOBALMARKET, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 24     INSTRUMENTS GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
      • TABLE 25     CONSUMABLES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
      • TABLE 26     SOFTWARE & SERVICES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
      • TABLE 27     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
      • TABLE 28     PRE-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 29     POST-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 30     TRANSPLANT DIAGNOSTIC GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 31     DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE (2014-2022) ($MN)
      • TABLE 32     DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 33     SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 34     SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 35     KIDNEY TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 36     HEART TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 37     LIVER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 38     OTHER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 39     STEM CELL TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 40     TISSUE BASED TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 41     RESEARCH APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 42     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 43     HOSPITALS AND TRANSPLANT CENTRES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 44     DIAGNOSTIC LABORATRIES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 45     RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 46     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 47     NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 48     NORTH AMERICAN MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 49     NORTH AMERICAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 50     NORTH AMERICAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 51     NORTH AMERICAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 52     NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 53     NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
      • TABLE 54     NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 55     NORTH AMERICAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 56     NORTH AMERICAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 57     NORTH AMERICAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 58     EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 59     EUROPEAN MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 60     EUROPEAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 61     EUROPEAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 62     EUROPEAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 63     EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
      • TABLE 64     EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 65     EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 66     EUROPEAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 67     EUROPEAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 68     EUROPEAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 69     ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 70     ASIA-PACIFIC MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 71     ASIA-PACIFIC PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 72     ASIA-PACIFIC SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 73     ASIA-PACIFIC NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 74     ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
      • TABLE 75     ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 76     ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 77     ASIA-PACIFIC DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 78     ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 79     ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 80     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 81     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 82     REST OF THE WORLD PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 83     REST OF THE WORLD SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 84     REST OF THE WORLD NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 85     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
      • TABLE 86     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 87     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 88     REST OF THE WORLD DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 89     REST OF THE WORLD SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 90     REST OF THE WORLD TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 91     ACQUISITIONS (2014-2016)
      • TABLE 92     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2016)
      • TABLE 93     NEW PRODUCT LAUNCHES (2014-2016)
      • TABLE 94     APPROVALS, (2014-2016)
      • TABLE 95     OTHER DEVELOPMENTS (2014-2016)
      • TABLE 96     ABBOTT LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 97     ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 98     ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 99     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 100     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 101     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 102     CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 103     ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 104     ILLUMINA, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 105     ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 106     IMMUCOR, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 107     IMMUCOR, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 108     IMMUCOR, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 109     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 110     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 111     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 112     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 113     ROCHE HOLDINGS AG:TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 114     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2013-2015) ($MN)
      • TABLE 115     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 116     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 117     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 118     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)

      LIST OF FIGURES

      • FIGURE 1     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • FIGURE 2     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: RESEARCH METHODOLOGY
      • FIGURE 3     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     TRANSPLANTATION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
      • FIGURE 10     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015 V’S 2022) ($MN)
      • FIGURE 11     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY MOLECUAR METHODS, (2015 V’S 2022) ($MN)
      • FIGURE 12     PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 13     SEQUENCING BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 14     NON-MOLECUAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 15     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2015 V’S 2022) ($MN)
      • FIGURE 16     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2015 V’S 2022) ($MN)
      • FIGURE 17     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 18     DIAGNOSTIC (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 19     SOLID ORGAN TRANSPLANTATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 20     TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2015 V’S 2022) ($MN)
      • FIGURE 21     TRANSPLANTATION DIANOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • FIGURE 22     NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 23     EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 24     ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 25     REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 26     KEY GROWTH STRATEGIES, (2014-2016)
      • FIGURE 27     SWOT: ABBOTT LABORATORIES, INC.
      • FIGURE 28     SWOT: BIOFORTUNA LTD
      • FIGURE 29     SWOT: BIO-RAD LABORATORIES
      • FIGURE 30     SWOT: CAREDX, INC.
      • FIGURE 31     SWOT: ILLUMINA, INC.
      • FIGURE 32     SWOT: IMMUCOR, INC.
      • FIGURE 33     SWOT: LINKAGE BIOSCIENCES
      • FIGURE 34     SWOT: QIAGEN N.V.
      • FIGURE 35     SWOT: ROCHE HOLDINGS AG
      • FIGURE 36     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN REPORT

      • 1     ABBOTT LABORATORIES
      • 2     ADAPTIVE BIOTECHNOLOGIES
      • 3     BAG HEALTH CARE GMBH
      • 4     BD BIOSCIENCES
      • 5     BIOFORTUNA LTD
      • 6     BIOMERIEUX
      • 7     BIO-RAD LABORATORIES
      • 8     BGI
      • 9     CAREDX, INC.
      • 10     CHRONIX BIOMEDICAL
      • 11     CYCLEX, INC.
      • 12     DANAHER CORPORATION
      • 13     DIAGNOMICS
      • 14     EXOSOME DIAGNOSTICS, INC.
      • 15     FUJIREBIO DIAGNOSTICS, INC.
      • 16     GENDX
      • 17     GMSBIOTECH
      • 18     HISTOGENETICS LLC
      • 19     HTG MOLECULAR DIAGNOSTICS
      • 20     ILLUMINA, INC.
      • 21     IMMUCOR, INC.
      • 22     INTERPRETOMICS INDIA PVT LTD
      • 23     LABS, INC.
      • 24     LINKAGE BIOSCIENCES
      • 25     LOPHIUS BIOSCIENCES GMBH
      • 26     LUMINEX CORPORATION
      • 27     OMIXON
      • 28     QIAGEN N.V.
      • 29     QUEST DIAGNOSTICS
      • 30     ROCHE HOLDINGS AG
      • 31     ROSE GENTEC LTD.
      • 32     SIGMA-ALDRICH (MERCK KGAA)
      • 33     SOFTGENETICS
      • 34     SRL DIAGNOSTICS
      • 35     TAI DIAGNOSTICS
      • 36     TBG DIAGNOSTICS LIMITED
      • 37     TRANSPLANT GENOMICS, INC.
      • 38     THERMO FISHER SCIENTIFIC, INC.
      • 39     XENO DIAGNOSTICS, LLC